Wednesday, March 09, 2022 7:42:00 AM
Regarding egfr which was what you were asking about if not a typo, my guess is a solid "maybe". BID dosing did not seem to make much of a difference in HER2 first line but could it be that these patients are a lot less sicker and able to stomach the once daily 16mg dose much easier than a second or third line patient which was the case in cohort 1? If that is the case and a much sicker 2nd or 3rd line patient is able to stay on BID dosing longer that might make a considerable difference in efficacy and boost it over 20% from the 14.8% we saw in cohort 1. Also w cohort 1 there was, I suspect, a big learning curve in how to administer the drug which won't be the case if they run another trial. Hopefully, we'll get better color after the quarterly CC later this month.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM